Jacob Bell's articles Biotechnology In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The decision to turn down an application from Lykos Therapeutics comes at a pivotal time for psychedelics research, which, after decades of dismissal, has recently gained momentum. Written by Jacob Bell August 11, 2024August 11, 2024 Saving Bookmark this article Bookmarked Biotechnology Lilly to buy Morphic in $3B bet on inflammation drug The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease. Written by Jacob Bell July 9, 2024July 9, 2024 Saving Bookmark this article Bookmarked Biotechnology Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi An under-the-skin injection of Leqembi performed about the same as the already marketed intravenous form, according to trial results presented Wednesday. A new approval application is expected by the end of March. Written by Jacob Bell October 26, 2023October 26, 2023 Saving Bookmark this article Bookmarked Biotechnology Roche is stuck on molecular glue One month after Roche’s Genentech inked a similar deal, the Swiss pharma is now paying $50 million to work with Monte Rosa on molecular glue medicines for cancer and neurological diseases. Written by Jacob Bell October 18, 2023October 18, 2023 Saving Bookmark this article Bookmarked
Biotechnology In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The decision to turn down an application from Lykos Therapeutics comes at a pivotal time for psychedelics research, which, after decades of dismissal, has recently gained momentum. Written by Jacob Bell August 11, 2024August 11, 2024 Saving Bookmark this article Bookmarked
Biotechnology Lilly to buy Morphic in $3B bet on inflammation drug The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease. Written by Jacob Bell July 9, 2024July 9, 2024 Saving Bookmark this article Bookmarked
Biotechnology Eisai says new data could support more convenient form of Alzheimer’s drug Leqembi An under-the-skin injection of Leqembi performed about the same as the already marketed intravenous form, according to trial results presented Wednesday. A new approval application is expected by the end of March. Written by Jacob Bell October 26, 2023October 26, 2023 Saving Bookmark this article Bookmarked
Biotechnology Roche is stuck on molecular glue One month after Roche’s Genentech inked a similar deal, the Swiss pharma is now paying $50 million to work with Monte Rosa on molecular glue medicines for cancer and neurological diseases. Written by Jacob Bell October 18, 2023October 18, 2023 Saving Bookmark this article Bookmarked
